Pharmacological Modulation of TRIB2 Stability in Melanoma Reveals CDK12/13 as Dominant Regulators and Potential Therapeutic Targets
V. Mayoral-Varo, A. Orea-Soufi, L. Jimenez, B. Santos, C. Amenabar, P. Kyriakou, G. Serrao, M. Jociles, S. Obeso, C. Garnes-Garcia, P. Fernandez-Aroca, R. s. Sanchez-Prieto, B. Ferreira, W. Link
This study identifies CDK12/13 as key regulators of TRIB2 stability in melanoma and presents three classes of compounds that effectively eliminate TRIB2 with higher potency than afatinib.
bioRxiv · Jul 17, 2024 · PreprintCancer Biology